https://semaglutides.org/news/2026/#rule-702-general-causation-hearing-opens-mdl-3094-20262026-09-15T01:35:26Zweekly https://semaglutides.org/news/2026/#status-check-two-unreconciled-medicare-semaglutide-prices-2027-20262026-09-15T03:04:33Zweekly https://semaglutides.org/news/2026/#status-check-no-glp-1-injury-settlement-no-20262026-09-15T03:04:58Zweekly https://semaglutides.org/news/2026/#truveta-19-percent-jump-glp-1-prescribing-seniors-after-bridge-20262026-09-15T01:36:17Zweekly https://semaglutides.org/news/2026/#step-young-obesityweek-20262026-09-15T01:36:03Zweekly https://semaglutides.org/news/2026/#novo-halts-hermes-athena-ziltivekimab-trials-20262026-09-15T03:05:01Zweekly https://semaglutides.org/news/2026/#only-indiana-commits-balance-medicaid-model-29-states-decline-20262026-09-15T03:05:06Zweekly https://semaglutides.org/news/2026/#fda-updates-unapproved-glp-1-guidance-compounded-tirzepatide-20262026-09-15T03:04:54Zweekly https://semaglutides.org/news/2026/#glp-1-injury-dockets-reach-4-022-216-20262026-09-15T03:05:03Zweekly https://semaglutides.org/news/2026/#rule-702-expert-hearing-tests-whether-glp-1-20262026-09-15T03:05:11Zweekly https://semaglutides.org/news/2026/#medicare-glp-1-bridge-enrollment-passes-half-million-20262026-09-15T03:05:28Zweekly https://semaglutides.org/news/2026/#lilly-cardiovascular-indication-dual-gip-glp-1-agonist-20262026-09-15T03:05:27Zweekly https://semaglutides.org/news/2026/#lilly-mounjaro-heart-indication-built-head-head-trial-20262026-09-15T03:05:44Zweekly https://semaglutides.org/news/2026/#mounjaro-cv-filing-20262026-09-15T03:05:34Zweekly https://semaglutides.org/news/2026/#fda-approves-mounjaro-cardiovascular-indication-20262026-09-15T03:05:40Zweekly https://semaglutides.org/news/2026/#fifth-circuit-upholds-fdas-glp-1-shortage-delistings-20262026-09-15T03:05:39Zweekly https://semaglutides.org/news/2026/#fda-records-novo-nordisk-notice-saxenda-will-discontinued-20262026-09-15T03:05:59Zweekly https://semaglutides.org/news/2026/#kff-documents-medicare-bridge-excludes-5-9-million-sicker-patients-20262026-09-15T03:05:51Zweekly https://semaglutides.org/news/2026/#lilly-files-lawsuits-retatrutide-gray-market-20262026-09-15T03:06:02Zweekly https://semaglutides.org/news/2026/#antitrust-suit-dismissed-20262026-09-15T03:06:04Zweekly https://semaglutides.org/news/2026/#cms-extends-medicare-glp-1-bridge-through-december-20262026-09-15T03:06:11Zweekly https://semaglutides.org/news/2026/#eli-lilly-48-revenue-growth-raises-2026-guidance2026-09-15T03:06:13Zweekly https://semaglutides.org/news/2026/#lilly-q2-revenue-jumps-48-23-billion-while-20262026-09-15T03:06:21Zweekly https://semaglutides.org/news/2026/#lilly-self-pay-now-zepbound-prescriptions-20262026-09-15T03:06:34Zweekly https://semaglutides.org/news/2026/#mounjaro-zepbound-top-14-8-billion-single-quarter-20262026-09-15T03:06:32Zweekly https://semaglutides.org/news/2026/#novo-q2-2026-raises-outlook2026-09-15T03:06:41Zweekly https://semaglutides.org/news/2026/#ziltivekimab-fails-zeus-heart-trial-erasing-30-billion-20262026-09-15T03:06:43Zweekly https://semaglutides.org/news/2026/#ftc-utah-los-angeles-county-sue-hims-hers-20262026-09-15T03:06:41Zweekly https://semaglutides.org/news/2026/#triumph-2-3-results-20262026-09-15T03:06:54Zweekly https://semaglutides.org/news/2026/#novo-challenges-lilly-ads-20262026-09-15T03:07:04Zweekly https://semaglutides.org/news/2026/#president-phased-tariffs-imported-generic-drugs-20262026-09-15T03:07:07Zweekly https://semaglutides.org/news/2026/#ec-approves-wegovy-pill-20262026-09-15T03:07:16Zweekly https://semaglutides.org/news/2026/#bmj-network-meta-analysis-biggest-fat-loss-biggest-20262026-09-15T03:07:16Zweekly https://semaglutides.org/news/2026/#gallup-11-adults-now-take-glp-1-weight-20262026-09-15T03:07:15Zweekly https://semaglutides.org/news/2026/#medicare-bridge-live-20262026-09-15T03:07:29Zweekly https://semaglutides.org/news/2026/#medicare-glp-1-bridge-publishing-explicit-bmi-eligibility-20262026-09-15T03:07:37Zweekly https://semaglutides.org/news/2026/#health-canada-approves-generic-semaglutide-weight-loss-20262026-09-15T03:07:37Zweekly https://semaglutides.org/news/2026/#pwc-finds-one-five-households-now-includes-glp-20262026-09-15T03:07:41Zweekly https://semaglutides.org/news/2026/#wegovy-pill-3m-scripts-20262026-09-15T03:07:51Zweekly https://semaglutides.org/news/2026/#cvs-restores-zepbound-announcement-20262026-09-15T03:07:45Zweekly https://semaglutides.org/news/2026/#bari-step-semaglutide-rescues-poor-weight-loss-bariatric-20262026-09-15T03:08:10Zweekly https://semaglutides.org/news/2026/#retatrutide-triumph-1-20262026-09-15T03:08:06Zweekly https://semaglutides.org/news/2026/#triumph-1-topline-retatrutide-reaches-28-3-weight-20262026-09-15T03:08:06Zweekly https://semaglutides.org/news/2026/#attain-maintain-tests-switching-injection-oral-glp-1-20262026-09-15T03:08:08Zweekly https://semaglutides.org/news/2026/#surmount-maintain-lancet-20262026-09-15T03:08:20Zweekly https://semaglutides.org/news/2026/#medicare-glp1-bridge-announced-20262026-09-15T03:08:17Zweekly https://semaglutides.org/news/2026/#mounjaro-passes-keytruda-worlds-best-selling-drug-20262026-09-15T03:08:31Zweekly https://semaglutides.org/news/2026/#ozempic-tablets-available-20262026-09-15T03:08:37Zweekly https://semaglutides.org/news/2026/#fda-503b-bulk-proposal-20262026-09-15T03:08:37Zweekly https://semaglutides.org/news/2026/#fda-proposes-exclude-semaglutide-tirzepatide-liraglutide-503b-bulks-20262026-09-15T03:08:42Zweekly https://semaglutides.org/news/2026/#lilly-60-1-incretin-market-share-20262026-09-15T03:08:47Zweekly https://semaglutides.org/news/2026/#nih-randomized-win-glp-1-drug-alcohol-use-20262026-09-15T03:08:53Zweekly https://semaglutides.org/news/2026/#health-canada-approves-generic-semaglutide-g7-20262026-09-15T03:08:58Zweekly https://semaglutides.org/news/2026/#cms-shelves-balance-model-medicare-part-d-extends-20262026-09-15T03:09:07Zweekly https://semaglutides.org/news/2026/#achieve-4-results-20262026-09-15T03:09:09Zweekly https://semaglutides.org/news/2026/#foundayo-goes-sale-united-states-20262026-09-15T03:09:13Zweekly https://semaglutides.org/news/2026/#foundayo-launch-20262026-09-15T03:09:18Zweekly https://semaglutides.org/news/2026/#section-232-pharmaceutical-tariff-proclamation-sets-lillys-rate-20262026-09-15T03:09:25Zweekly https://semaglutides.org/news/2026/#foundayo-approval-20262026-09-15T03:09:39Zweekly https://semaglutides.org/news/2026/#fda-clarifies-compounding-rules-glp-1-supply-stabilizes-20262026-09-15T03:09:32Zweekly https://semaglutides.org/news/2026/#fda-clarifies-essentially-copy-rule-four-prescription-threshold-20262026-09-15T03:09:35Zweekly https://semaglutides.org/news/2026/#fda-sets-four-prescriptions-yardstick-copy-compounding-20262026-09-15T03:09:39Zweekly https://semaglutides.org/news/2026/#fda-spells-what-counts-essentially-copy-compounded-glp-20262026-09-15T03:09:47Zweekly https://semaglutides.org/news/2026/#foundayo-orforglipron-approval-creates-biggest-comparison-opportunity-20262026-09-15T03:09:59Zweekly https://semaglutides.org/news/2026/#tos-oma-oac-give-continuing-medication-during-maintenance-20262026-09-15T03:10:02Zweekly https://semaglutides.org/news/2026/#meta-analysis-puts-number-what-resistance-training-changes-20262026-09-15T03:10:06Zweekly https://semaglutides.org/news/2026/#dozen-indian-generic-semaglutide-brands-one-20262026-09-15T03:10:06Zweekly https://semaglutides.org/news/2026/#china-brazil-patent-expiry-20262026-09-15T03:10:21Zweekly https://semaglutides.org/news/2026/#india-patent-expiry-20262026-09-15T03:10:15Zweekly https://semaglutides.org/news/2026/#wegovy-hd-approval-20262026-09-15T03:10:38Zweekly https://semaglutides.org/news/2026/#imcivree-becomes-approved-treatment-acquired-hypothalamic-obesity-20262026-09-15T03:10:31Zweekly https://semaglutides.org/news/2026/#zepbound-kwikpen-self-pay-pricing-reaches-pharmacies-nationwide-20262026-09-15T03:10:36Zweekly https://semaglutides.org/news/2026/#novo-hims-settlement-20262026-09-15T03:10:37Zweekly https://semaglutides.org/news/2026/#eli-lilly-employer-connect-selling-zepbound-employers-449-20262026-09-15T03:10:43Zweekly https://semaglutides.org/news/2026/#fda-warning-letter-pade-20262026-09-15T03:10:49Zweekly https://semaglutides.org/news/2026/#meta-regression-maps-shape-weight-regain-stopping-glp-20262026-09-15T03:10:57Zweekly https://semaglutides.org/news/2026/#fda-30-warning-letters-20262026-09-15T03:11:06Zweekly https://semaglutides.org/news/2026/#novo-list-price-cut-20262026-09-15T03:11:07Zweekly https://semaglutides.org/news/2026/#cagrisema-loses-tirzepatide-redefine-4-novo-nordisk-shares-20262026-09-15T03:11:05Zweekly https://semaglutides.org/news/2026/#redefine-4-miss-20262026-09-15T03:11:15Zweekly https://semaglutides.org/news/2026/#lilly-zepbound-kwikpen-same-self-pay-price-vial-20262026-09-15T03:11:19Zweekly https://semaglutides.org/news/2026/#fda-issues-30-warning-letters-telehealth-companies-marketing-20262026-09-15T03:11:24Zweekly https://semaglutides.org/news/2026/#circuit-upholds-health-plans-weight-loss-drug-exclusion-20262026-09-15T03:11:42Zweekly https://semaglutides.org/news/2026/#largest-naion-study-date-va-cohort-finds-double-20262026-09-15T03:11:42Zweekly https://semaglutides.org/news/2026/#novo-sues-hims-20262026-09-15T03:11:38Zweekly https://semaglutides.org/news/2026/#glp1-super-bowl-20262026-09-15T03:11:56Zweekly https://semaglutides.org/news/2026/#fda-restricts-glp1-compounding-20262026-09-15T03:11:48Zweekly https://semaglutides.org/news/2026/#fda-threatens-seizure-injunction-compounded-glp-1-marketing-20262026-09-15T03:11:52Zweekly https://semaglutides.org/news/2026/#trumprx-launches-20262026-09-15T03:12:06Zweekly https://semaglutides.org/news/2026/#hims-49-pill-launch-20262026-09-15T03:12:15Zweekly https://semaglutides.org/news/2026/#trumprx-gov-glp-1-coupons-20262026-09-15T03:12:13Zweekly https://semaglutides.org/news/2026/#lilly-2025-results-mounjaro-23-0-billion-zepbound-20262026-09-15T03:12:19Zweekly https://semaglutides.org/news/2026/#lilly-2025-revenue-65-2-billion-45-guides-20262026-09-15T03:12:25Zweekly https://semaglutides.org/news/2026/#novo-shares-plunge-feb-20262026-09-15T03:12:29Zweekly https://semaglutides.org/news/2026/#full-2025-results-sales-dkk-309-1-billion-20262026-09-15T03:12:38Zweekly https://semaglutides.org/news/2026/#novo-2026-guidance-shock2026-09-15T03:12:45Zweekly https://semaglutides.org/news/2026/#analysts-trim-obesity-drug-market-forecasts-30-20262026-09-15T03:12:46Zweekly https://semaglutides.org/news/2026/#rest-trial-recruiting-randomized-test-tapering-versus-stopping-20262026-09-15T03:12:48Zweekly https://semaglutides.org/news/2026/#zepbounds-suicidal-ideation-warning-removed-severe-gastrointestinal-section-20262026-09-15T03:12:59Zweekly https://semaglutides.org/news/2026/#mhra-strengthens-pancreatitis-warnings-entire-glp-1-class-20262026-09-15T03:13:03Zweekly https://semaglutides.org/news/2026/#ira-round-three-selection-20262026-09-15T03:13:07Zweekly https://semaglutides.org/news/2026/#fda-approves-mounjaro-kwikpen-zepbound-kwikpen-20262026-09-15T03:13:16Zweekly https://semaglutides.org/news/2026/#kff-counts-13-state-medicaid-programs-covering-glp-20262026-09-15T03:13:14Zweekly https://semaglutides.org/news/2026/#fda-asks-drugmakers-drop-suicidal-thoughts-warning-glp-20262026-09-15T03:13:20Zweekly https://semaglutides.org/news/2026/#obesity-association-publishes-2026-pharmacologic-treatment-standards-ranking2026-09-15T03:13:40Zweekly https://semaglutides.org/news/2026/#wegovy-pill-launch-20262026-09-15T03:13:32Zweekly https://semaglutides.org/news/2026/#wegovy-pill-oral-glp-1-approved-obesity-20262026-09-15T03:13:46Zweekly https://semaglutides.org/news/2026/#novo-nordisks-canadian-data-exclusivity-semaglutide-expires-20262026-09-15T03:13:47Zweekly https://semaglutides.org/news/2026/#michigan-medicaid-restricts-glp-1-obesity-coverage-bmi-20262026-09-15T03:13:49Zweekly https://semaglutides.org/news/2026/#semaglutide-exclusivity-expiring-outside-united-states-20262026-09-15T03:13:56Zweekly https://semaglutides.org/news/2025/#oprah-reveals-she-stopped-glp-1s-regained-20-20252026-09-15T03:14:06Zweekly https://semaglutides.org/news/2025/#cms-introduces-balance-model-glp-1-coverage-medicare-20252026-09-15T03:14:15Zweekly https://semaglutides.org/news/2025/#fda-approval-wegovy-pill-opens-highest-growth-query-20252026-09-15T03:14:20Zweekly https://semaglutides.org/news/2025/#wegovy-pill-approved-20252026-09-15T03:14:25Zweekly https://semaglutides.org/news/2025/#fda-expands-mounjaro-children-aged-10-older-20252026-09-15T03:14:21Zweekly https://semaglutides.org/news/2025/#journal-marketing-research-publishes-definitive-glp-1-grocery-20252026-09-15T03:14:25Zweekly https://semaglutides.org/news/2025/#novo-nordisk-files-cagrisema-fda-20252026-09-15T03:14:41Zweekly https://semaglutides.org/news/2025/#orforglipron-holds-weight-loss-patients-switch-off-injections-20252026-09-15T03:14:57Zweekly https://semaglutides.org/news/2025/#surpass-cvot-published-tirzepatide-non-inferior-dulaglutide-20252026-09-15T03:14:51Zweekly https://semaglutides.org/news/2025/#surpass-cvot-published-england-journal-medicine-2025-22026-09-15T03:14:59Zweekly https://semaglutides.org/news/2025/#mdl-3163-created-20252026-09-15T03:15:06Zweekly https://semaglutides.org/news/2025/#jpml-creates-mdl-3163-eli-lillys-motion-declining-20252026-09-15T03:14:59Zweekly https://semaglutides.org/news/2025/#mounjaro-approved-children-10-older-type-2-diabetes-20252026-09-15T03:15:12Zweekly https://semaglutides.org/news/2025/#retatrutide-delivers-71-2-pounds-average-weight-loss-20252026-09-15T03:15:15Zweekly https://semaglutides.org/news/2025/#retatrutides-phase-3-win-28-7-weight-loss-20252026-09-15T03:15:25Zweekly https://semaglutides.org/news/2025/#surpass-cvot-published-england-journal-medicine-20252026-09-15T03:15:31Zweekly https://semaglutides.org/news/2025/#adas-2026-standards-care-name-semaglutide-tirzepatide-preferred-20252026-09-15T03:15:35Zweekly https://semaglutides.org/news/2025/#fda-seizes-counterfeit-ozempic-labeled-authentic-lot-number-20252026-09-15T03:15:33Zweekly https://semaglutides.org/news/2025/#ftc-approves-final-order-against-telehealth-provider-nextmed-20252026-09-15T03:15:32Zweekly https://semaglutides.org/news/2025/#eli-lilly-cuts-zepbound-single-dose-vial-prices-20252026-09-15T03:15:45Zweekly https://semaglutides.org/news/2025/#mounjaro-adds-pediatric-indication-severe-gastrointestinal-adverse-reactions-20252026-09-15T03:16:02Zweekly https://semaglutides.org/news/2025/#cms-negotiated-price-semaglutide-20252026-09-15T03:16:06Zweekly https://semaglutides.org/news/2025/#evoke-alzheimers-failure-20252026-09-15T03:16:01Zweekly https://semaglutides.org/news/2025/#eli-lilly-becomes-drugmaker-worth-1-trillion-20252026-09-15T03:16:03Zweekly https://semaglutides.org/news/2025/#novo-199-intro-offer-20252026-09-15T03:16:08Zweekly https://semaglutides.org/news/2025/#kff-finds-18-adults-have-ever-used-glp-20252026-09-15T03:16:16Zweekly https://semaglutides.org/news/2025/#novo-egm-board-takeover-20252026-09-15T03:16:30Zweekly https://semaglutides.org/news/2025/#pfizer-wins-metsera-20252026-09-15T03:16:36Zweekly https://semaglutides.org/news/2025/#lilly-agrees-trump-administration-cut-zepbound-prices-20252026-09-15T03:16:34Zweekly https://semaglutides.org/news/2025/#mfn-glp1-pricing-deal-20252026-09-15T03:16:42Zweekly https://semaglutides.org/news/2025/#lilly-government-agree-tirzepatide-pricing-including-50-medicare-20252026-09-15T03:16:40Zweekly https://semaglutides.org/news/2025/#trump-glp-1-price-deals-calls-them-fat-20252026-09-15T03:16:49Zweekly https://semaglutides.org/news/2025/#white-house-deal-sets-245-medicare-price-trumprx-20252026-09-15T03:17:03Zweekly https://semaglutides.org/news/2025/#zepbound-overtakes-wegovy-20252026-09-15T03:17:07Zweekly https://semaglutides.org/news/2025/#zepbound-tops-keytruda-20252026-09-15T03:17:05Zweekly https://semaglutides.org/news/2025/#novo-board-resignations-20252026-09-15T03:17:13Zweekly https://semaglutides.org/news/2025/#rybelsus-cv-indication-20252026-09-15T03:17:12Zweekly https://semaglutides.org/news/2025/#all-semaglutide-labels-gain-severe-gastrointestinal-adverse-reactions-20252026-09-15T03:17:29Zweekly https://semaglutides.org/news/2025/#trumprx-announced-20252026-09-15T03:17:33Zweekly https://semaglutides.org/news/2025/#oasis-4-published-oral-semaglutide-25-mg-produces-20252026-09-15T03:17:42Zweekly https://semaglutides.org/news/2025/#surpass-cvot-presented-full-easd-2025-vienna2026-09-15T03:17:41Zweekly https://semaglutides.org/news/2025/#orforglipron-beats-oral-semaglutide-head-head-type-2-20252026-09-15T03:17:48Zweekly https://semaglutides.org/news/2025/#oasis-4-published-20252026-09-15T03:17:47Zweekly https://semaglutides.org/news/2025/#attain-1-published-lillys-oral-glp-1-pill-20252026-09-15T03:17:54Zweekly https://semaglutides.org/news/2025/#fda-hhs-compounder-letters-20252026-09-15T03:18:02Zweekly https://semaglutides.org/news/2025/#step-published-semaglutide-7-2-mg-pushes-weight-20252026-09-15T03:18:10Zweekly https://semaglutides.org/news/2025/#novo-9000-layoffs-20252026-09-15T03:18:18Zweekly https://semaglutides.org/news/2025/#fda-ad-warning-letters-20252026-09-15T03:18:22Zweekly https://semaglutides.org/news/2025/#fda-sends-hims-hers-warning-letter-compounded-semaglutide-20252026-09-15T03:18:14Zweekly https://semaglutides.org/news/2025/#fda-creates-glp-1-api-green-list-import-20252026-09-15T03:18:29Zweekly https://semaglutides.org/news/2025/#gallup-obesity-rate-falling-37-0-glp-1-20252026-09-15T03:18:33Zweekly https://semaglutides.org/news/2025/#teva-generic-glp-1-indicated-weight-loss-20252026-09-15T03:18:37Zweekly https://semaglutides.org/news/2025/#attain-2-completes-orforglipron-obesity-package-20252026-09-15T03:18:40Zweekly https://semaglutides.org/news/2025/#serena-williams-goes-public-zepbound-joins-ro-20252026-09-15T03:18:53Zweekly https://semaglutides.org/news/2025/#wegovy-mash-approval-20252026-09-15T03:18:54Zweekly https://semaglutides.org/news/2025/#mdl-objective-testing-20252026-09-15T03:18:58Zweekly https://semaglutides.org/news/2025/#attain-1-topline-27-3-pounds-lost-highest-20252026-09-15T03:19:10Zweekly https://semaglutides.org/news/2025/#doustdar-becomes-ceo-20252026-09-15T03:19:10Zweekly https://semaglutides.org/news/2025/#mdl-judge-rules-what-evidence-supports-gastroparesis-claim-20252026-09-15T03:19:14Zweekly https://semaglutides.org/news/2025/#lilly-surpass-cvot-topline-non-inferior-heart-events-20252026-09-15T03:19:18Zweekly https://semaglutides.org/news/2025/#surpass-cvot-topline-20252026-09-15T03:19:24Zweekly https://semaglutides.org/news/2025/#profit-warning-wipes-70-billion-off-novo-nordisks-20252026-09-15T03:19:26Zweekly https://semaglutides.org/news/2025/#surmount-5-confirms-tirzepatide-beats-semaglutide-weight-head-20252026-09-15T03:20:38Zweekly https://semaglutides.org/news/2025/#cvs-caremark-forces-largest-molecule-switch-class-date-20252026-09-15T03:19:46Zweekly https://semaglutides.org/news/2025/#cvs-zepbound-class-action-20252026-09-15T03:19:47Zweekly https://semaglutides.org/news/2025/#novo-ends-hims-deal-20252026-09-15T03:19:50Zweekly https://semaglutides.org/news/2025/#redefine-1-2-published-cagrisema-passes-20-weight-20252026-09-15T03:19:56Zweekly https://semaglutides.org/news/2025/#ema-naion-conclusion-20252026-09-15T03:19:50Zweekly https://semaglutides.org/news/2025/#federal-judge-rules-fda-novo-merits-semaglutide-shortage-20252026-09-15T03:20:18Zweekly https://semaglutides.org/news/2025/#cleveland-clinic-study-explains-trial-versus-real-world-20252026-09-15T03:20:17Zweekly https://semaglutides.org/news/2025/#ema-adds-sudden-vision-loss-european-semaglutide-labels-20252026-09-15T03:20:12Zweekly https://semaglutides.org/news/2025/#ema-declares-naion-very-rare-side-effect-semaglutide-20252026-09-15T03:21:21Zweekly https://semaglutides.org/news/2025/#503b-deadline-20252026-09-15T03:20:29Zweekly https://semaglutides.org/news/2025/#novo-ceo-ousted-20252026-09-15T03:20:37Zweekly https://semaglutides.org/news/2025/#mfn-executive-order-20252026-09-15T03:20:48Zweekly https://semaglutides.org/news/2025/#surmount-5-tirzepatide-beats-semaglutide-head-head-obesity-20252026-09-15T03:20:54Zweekly https://semaglutides.org/news/2025/#district-court-grants-summary-judgment-fda-tirzepatide-case-20252026-09-15T03:21:01Zweekly https://semaglutides.org/news/2025/#weightwatchers-bankruptcy-20252026-09-15T03:21:10Zweekly https://semaglutides.org/news/2025/#cvs-caremark-will-drop-zepbound-standard-commercial-formularies-20252026-09-15T03:21:10Zweekly https://semaglutides.org/news/2025/#cvs-wegovy-preferred-20252026-09-15T03:21:16Zweekly https://semaglutides.org/news/2025/#essence-part-1-shows-semaglutide-reverses-liver-inflammation-20252026-09-15T03:21:24Zweekly https://semaglutides.org/news/2025/#novo-telehealth-partnerships-20252026-09-15T03:21:33Zweekly https://semaglutides.org/news/2025/#federal-court-denies-injunction-sought-compounders-semaglutide-20252026-09-15T03:21:38Zweekly https://semaglutides.org/news/2025/#eli-lilly-sues-four-telehealth-companies-compounded-tirzepatide-20252026-09-15T03:21:38Zweekly https://semaglutides.org/news/2025/#503a-deadline-20252026-09-15T03:21:53Zweekly https://semaglutides.org/news/2025/#achieve-1-topline-20252026-09-15T03:21:48Zweekly https://semaglutides.org/news/2025/#anaesthesia-meta-analysis-retained-stomach-contents-no-measurable-20252026-09-15T03:21:51Zweekly https://semaglutides.org/news/2025/#itc-issues-general-exclusion-order-infringing-tirzepatide-imports-20252026-09-15T03:22:00Zweekly https://semaglutides.org/news/2025/#essence-published-semaglutide-resolves-mash-treated-patients-20252026-09-15T03:22:08Zweekly https://semaglutides.org/news/2025/#soul-acc-nejm-20252026-09-15T03:22:08Zweekly https://semaglutides.org/news/2025/#enforcement-discretion-ends-503b-outsourcing-facilities-compounding-tirzepatide-20252026-09-15T03:22:22Zweekly https://semaglutides.org/news/2025/#court-denies-compounders-injunction-tirzepatide-20252026-09-15T03:22:23Zweekly https://semaglutides.org/news/2025/#novocare-pharmacy-499-20252026-09-15T03:22:26Zweekly https://semaglutides.org/news/2025/#lilly-27-billion-us-plants-20252026-09-15T03:22:25Zweekly https://semaglutides.org/news/2025/#fda-shortage-resolved-20252026-09-15T03:22:41Zweekly https://semaglutides.org/news/2025/#503a-compounding-tirzepatide-copies-loses-shortage-protection-20252026-09-15T03:22:45Zweekly https://semaglutides.org/news/2025/#enforcement-discretion-ends-503a-pharmacies-compounding-tirzepatide-20252026-09-15T03:22:50Zweekly https://semaglutides.org/news/2025/#randomized-trial-semaglutide-alcohol-use-disorder-published-20252026-09-15T03:22:56Zweekly https://semaglutides.org/news/2025/#hims-hers-runs-super-bowl-ad-glp-1-20252026-09-15T03:24:05Zweekly https://semaglutides.org/news/2025/#fda-adds-kidney-indication-ozempic-based-flow-20252026-09-15T03:22:50Zweekly https://semaglutides.org/news/2025/#ozempic-ckd-approval-20252026-09-15T03:23:12Zweekly https://semaglutides.org/news/2025/#semaglutide-ira-selected-20252026-09-15T03:23:15Zweekly https://semaglutides.org/news/2025/#three-surmount-1-data-show-93-relative-drop-20252026-09-15T03:23:24Zweekly https://semaglutides.org/news/2025/#medicare-covers-zepbound-osa-20252026-09-15T03:23:19Zweekly https://semaglutides.org/news/2025/#cornell-numerator-quantify-glp-1-grocery-effect-20252026-09-15T03:23:25Zweekly https://semaglutides.org/news/2024/#fda-approves-true-generic-victoza-20242026-09-15T03:23:39Zweekly https://semaglutides.org/news/2024/#cagrisema-redefine1-20242026-09-15T03:23:49Zweekly https://semaglutides.org/news/2024/#zepbound-osa-label-20242026-09-15T03:23:51Zweekly https://semaglutides.org/news/2024/#fda-reaffirms-tirzepatide-shortage-resolved-20242026-09-15T03:23:54Zweekly https://semaglutides.org/news/2024/#fda-issues-formal-declaratory-order-ending-tirzepatide-shortage-20242026-09-15T03:23:54Zweekly https://semaglutides.org/news/2024/#fda-reaffirms-tirzepatide-shortage-resolution-wind-clocks-20242026-09-15T03:24:10Zweekly https://semaglutides.org/news/2024/#surmount-5-topline-20242026-09-15T03:24:24Zweekly https://semaglutides.org/news/2024/#summit-published-aha-20242026-09-15T03:24:25Zweekly https://semaglutides.org/news/2024/#three-surmount-1-data-show-94-percent-lower-20242026-09-15T03:24:25Zweekly https://semaglutides.org/news/2024/#aspiration-warning-appears-semaglutide-tirzepatide-liraglutide-labels-20242026-09-15T03:24:22Zweekly https://semaglutides.org/news/2024/#five-medical-societies-reverse-course-patients-can-keep-20242026-09-15T03:24:31Zweekly https://semaglutides.org/news/2024/#astrazeneca-discontinues-byetta-united-states-20242026-09-15T03:24:47Zweekly https://semaglutides.org/news/2024/#soul-topline-20242026-09-15T03:24:49Zweekly https://semaglutides.org/news/2024/#ofa-sues-fda-20242026-09-15T03:24:56Zweekly https://semaglutides.org/news/2024/#tirzepatide-delisted-shortage-20242026-09-15T03:25:01Zweekly https://semaglutides.org/news/2024/#fda-declares-tirzepatide-shortage-resolved-october-2-20242026-09-15T03:24:56Zweekly https://semaglutides.org/news/2024/#novo-nordisks-ceo-grilled-bernie-sanders-glp-1-20242026-09-15T03:25:07Zweekly https://semaglutides.org/news/2024/#fda-orders-class-wide-anesthesia-warning-glp-1-20242026-09-15T03:25:16Zweekly https://semaglutides.org/news/2024/#zepbound-vials-399-20242026-09-15T03:25:18Zweekly https://semaglutides.org/news/2024/#surmount-1-three-year-diabetes-prevention-20242026-09-15T03:25:19Zweekly https://semaglutides.org/news/2024/#naion-harvard-study-20242026-09-15T03:25:34Zweekly https://semaglutides.org/news/2024/#novo-nordisks-listed-shares-close-all-time-high-20242026-09-15T03:25:33Zweekly https://semaglutides.org/news/2024/#teva-authorized-generic-victoza-20242026-09-15T03:25:36Zweekly https://semaglutides.org/news/2024/#surmount-osa-shows-tirzepatide-roughly-halves-sleep-apnea-20242026-09-15T03:25:48Zweekly https://semaglutides.org/news/2024/#lilly-publishes-open-letter-counterfeit-compounded-tirzepatide-20242026-09-15T03:25:49Zweekly https://semaglutides.org/news/2024/#flow-published-20242026-09-15T03:25:50Zweekly https://semaglutides.org/news/2024/#surmount-osa-topline-20242026-09-15T03:26:01Zweekly https://semaglutides.org/news/2024/#oprah-glp1-special-20242026-09-15T03:26:08Zweekly https://semaglutides.org/news/2024/#wegovy-cv-indication-20242026-09-15T03:26:24Zweekly https://semaglutides.org/news/2024/#zepbound-passes-wegovy-weekly-prescriptions-time-20242026-09-15T03:26:16Zweekly https://semaglutides.org/news/2024/#flow-topline-20242026-09-15T03:26:23Zweekly https://semaglutides.org/news/2024/#novo-catalent-deal-announced-20242026-09-15T03:26:18Zweekly https://semaglutides.org/news/2024/#mdl-3094-created-20242026-09-15T03:26:34Zweekly https://semaglutides.org/news/2024/#jpml-creates-mdl-3094-eli-lilly-named-defendant-20242026-09-15T03:26:43Zweekly https://semaglutides.org/news/2024/#lilly-lillydirect-direct-patient-platform-major-drugmaker-20242026-09-15T03:26:46Zweekly https://semaglutides.org/news/2024/#lillydirect-launch-detail-20242026-09-15T03:26:47Zweekly https://semaglutides.org/news/2023/#surmount-4-jama-20232026-09-15T03:27:00Zweekly https://semaglutides.org/news/2023/#oprah-winfrey-tells-people-she-uses-weight-loss-20232026-09-15T03:26:51Zweekly https://semaglutides.org/news/2023/#select-aha-nejm-20232026-09-15T03:27:06Zweekly https://semaglutides.org/news/2023/#fda-approves-zepbound-20232026-09-15T03:27:18Zweekly https://semaglutides.org/news/2023/#zepbound-approved-weight-management-carrying-suicidal-ideation-warning-20232026-09-15T03:27:22Zweekly https://semaglutides.org/news/2023/#zepbound-approval-label-20232026-09-15T03:27:16Zweekly https://semaglutides.org/news/2023/#jama-research-letter-links-glp-1-weight-loss-20232026-09-15T03:27:26Zweekly https://semaglutides.org/news/2023/#walmart-glp-1-users-buying-less-food-20232026-09-15T03:27:28Zweekly https://semaglutides.org/news/2023/#ozempic-ileus-warning-20232026-09-15T03:27:36Zweekly https://semaglutides.org/news/2023/#novo-most-valuable-europe-20232026-09-15T03:27:56Zweekly https://semaglutides.org/news/2023/#select-topline-20232026-09-15T03:27:50Zweekly https://semaglutides.org/news/2023/#retatrutide-phase-2-nejm-20232026-09-15T03:27:51Zweekly https://semaglutides.org/news/2023/#jimmy-kimmels-oscars-monologue-turns-ozempic-punchline-20232026-09-15T03:28:03Zweekly https://semaglutides.org/news/2023/#academy-pediatrics-issues-childhood-obesity-clinical-practice-guideline-20232026-09-15T03:28:00Zweekly https://semaglutides.org/news/2022/#fda-lists-mounjaro-shortage-20222026-09-15T03:28:01Zweekly https://semaglutides.org/news/2022/#fda-adds-tirzepatide-injection-drug-shortage-list-20222026-09-15T03:28:26Zweekly https://semaglutides.org/news/2022/#step-teens-published-semaglutide-cuts-bmi-16-1-20222026-09-15T03:28:19Zweekly https://semaglutides.org/news/2022/#fda-expands-wegovy-patients-12-older-obesity-20222026-09-15T03:28:27Zweekly https://semaglutides.org/news/2022/#surmount-1-sets-obesity-benchmark-20-9-weight-20222026-09-15T03:28:30Zweekly https://semaglutides.org/news/2022/#step-1-extension-shows-two-thirds-lost-weight-20222026-09-15T03:28:30Zweekly https://semaglutides.org/news/2022/#fda-approves-tirzepatide-dual-gip-glp-1-receptor-20222026-09-15T03:28:38Zweekly https://semaglutides.org/news/2022/#mounjaro-approved-thyroid-c-cell-boxed-warning-20222026-09-15T03:29:02Zweekly https://semaglutides.org/news/2022/#mounjaro-first-label-details-20222026-09-15T03:28:55Zweekly https://semaglutides.org/news/2022/#surmount-1-topline-20222026-09-15T03:28:52Zweekly https://semaglutides.org/news/2022/#step-1-extension-shows-weight-comes-back-semaglutide-20222026-09-15T03:29:02Zweekly https://semaglutides.org/news/2022/#wegovy-shortage-listed-20222026-09-15T03:28:59Zweekly https://semaglutides.org/news/2022/#step-8-shows-semaglutide-beats-liraglutide-3-0-20222026-09-15T03:29:13Zweekly https://semaglutides.org/news/2021/#obesity-society-publishes-definitive-supplement-review-16-315-20212026-09-15T03:29:19Zweekly https://semaglutides.org/news/2021/#surpass-2-shows-tirzepatide-beats-semaglutide-1-mg-20212026-09-15T03:29:26Zweekly https://semaglutides.org/news/2021/#fda-approves-wegovy-20212026-09-15T03:29:34Zweekly https://semaglutides.org/news/2021/#s-lite-shows-exercise-plus-glp-1-beats-20212026-09-15T03:29:41Zweekly https://semaglutides.org/news/2021/#step-4-shows-what-happens-when-semaglutide-stops-20212026-09-15T03:30:26Zweekly https://semaglutides.org/news/2021/#step-1-publishes-weight-loss-curve-anchors-every-20212026-09-15T03:29:43Zweekly https://semaglutides.org/news/2021/#step-1-nejm-20212026-09-15T03:29:54Zweekly https://semaglutides.org/news/2020/#fda-requests-withdrawal-lorcaserin-belviq-cancer-signal-20202026-09-15T03:29:54Zweekly https://semaglutides.org/news/2020/#lilly-manufacturing-buildout-strength-tirzepatide-phase-2-data-20202026-09-15T03:29:57Zweekly https://semaglutides.org/news/2019/#fda-approves-rybelsus-20192026-09-15T03:30:18Zweekly https://semaglutides.org/news/2019/#rewind-gives-trulicity-cardiovascular-indication-20192026-09-15T03:30:13Zweekly https://semaglutides.org/news/2018/#lilly-publishes-tirzepatide-discovery-paper-20182026-09-15T03:30:30Zweekly https://semaglutides.org/news/2018/#sustain-7-establishes-semaglutide-potent-glp-1-era-20182026-09-15T03:30:21Zweekly https://semaglutides.org/news/2017/#fda-approves-ozempic-20172026-09-15T03:30:27Zweekly https://semaglutides.org/news/2017/#ozempic-boxed-warning-20172026-09-15T03:30:43Zweekly https://semaglutides.org/news/2017/#david-ricks-becomes-chief-executive-eli-lilly-20172026-09-15T03:30:47Zweekly https://semaglutides.org/news/2016/#sustain-6-shows-semaglutide-cuts-heart-events-type-20162026-09-15T03:31:00Zweekly https://semaglutides.org/news/2016/#leader-shows-liraglutide-cuts-cardiovascular-death-20162026-09-15T03:30:58Zweekly https://semaglutides.org/news/2014/#saxenda-glp-1-approved-weight-management-20142026-09-15T03:31:02Zweekly